Autologous serum eyedrops in the treatment of aniridic keratopathy.
OBJECTIVE
To study the effect of autologous serum eyedrop application in aniridic keratopathy.


METHODS
Prospective, consecutive, comparative, interventional case series.


METHODS
Twenty-six eyes from 13 patients (7 males and 6 females) with aniridic keratopathy treated with autologous serum eyedrops.


METHODS
All patients underwent a complete ophthalmic examination. The ocular surface examinations included corneal impression cytologic analysis and tear film evaluation. The eyes were divided into 4 groups according to the Mackman classification. Ocular surface photography was used to evaluate the corneal surface and tear film before treatment and every 2 or 3 days until serum drops were stopped. Tear films were evaluated by tear film break-up time (BUT) (normal, 10 seconds or more), Schirmer's test with anesthesia (normal, 10 mm/5 minutes or more), tear meniscus level (normal, 0.5 mm or more), and rose bengal and fluorescein staining pattern of the cornea. Impression cytologic analysis was carried out both before starting the serum eyedrops treatment and a few days after its finalization.


METHODS
Tear film production and stability, corneal epithelialization, and corneal epithelium squamous metaplasia.


RESULTS
There were no local side effects from autologous serum treatment. Clinical manifestations and slit-lamp findings were in relation to the severity of keratopathy. All patients showed a subjective improvement of keratopathy symptoms after the autologous serum applications. The corneal epithelialization, corneal epithelial cell squamous metaplasia, and tear stability improved significantly with the treatment, but visual acuity, regression of vascular pannus, and subepithelial scarring showed only slight improvement with treatment.


CONCLUSIONS
Autologous serum eyedrops improved the aniridic keratopathy in all patients, particularly in patients with light or moderate severity. In these patients, use of autologous serum eyedrops was superior to conventional therapy with substitute tears for improving the ocular surface and subjective comfort.
López-García
J S
JS
Ophthalmology Service, Hospital Cruz Roja, Madrid, Spain. docsantilopez@hotmail.com
Rivas
L
L
García-Lozano
I
I
Murube
J
J
D000293:Adolescent; D000328:Adult; D015783:Aniridia / Q000097:blood / Q000628:therapy*; D002648:Child; D003316:Corneal Diseases / Q000097:blood / Q000628:therapy*; D005260:Female; D015590:Fluorophotometry; D006801:Humans; D007429:Intraocular Pressure; D008297:Male; D033401:Microscopy, Acoustic; D008875:Middle Aged; D009883:Ophthalmic Solutions / Q000627:therapeutic use*; D011446:Prospective Studies; D044967:Serum; D013666:Tears / Q000737:chemistry / Q000502:physiology; D014065:Tonometry, Ocular; D014792:Visual Acuity
D009883:Ophthalmic Solutions